Age |
|
As 5-year bins between 16 and 111 years |
Sex |
|
Male or female |
Vaccination status |
|
Not vaccinated; received a single-dose vaccine
(i) <14 days before COVID-19 diagnosis; ii) 14-90 days before
or (iii) >90 days before COVID-19 diagnosis; received the
1st dose of a two-dose vaccine (i) <14 days
before; (ii) 14-90 days before or (iii) >90 days before
COVID-19 diagnosis; received the 2nd dose of a
two-dose vaccine (i) <14 days before; (ii) 14-90 days before
or (iii) >90 days before COVID-19 diagnosis |
Calendar period |
|
Up to January 9 2020 (including) – still no
vaccination, Alpha strain(s) prevailing; January 10 – July 15 2021 –
Alpha strain(s) prevailing, mass vaccination in progress; after July 15
2021 – Delta strain starts to prevail, mass vaccination in
progress. |
Comorbidities |
|
Charlson comorbidity index (CCI) subseted at 4 levels:
0, 1-2, 3-4 and ≥5, and also individual comorbidities: atrial
fibrillation, autoimmune disease, malignant disease (cancer), congestive
heart failure, chronic obstructive pulmonary disease, history of
ischemic heart disease or a cerebrovascular disease, renal disease,
diabetes without complications, diabetes with
complications |
Pharmacological treatments |
|
Inhibitors of the
renin-angiotensine-aldosterone system (RAAS) (includes any of the
following: angiotensine converting enzyme inhibitors, angiotensine
receptor antagonists and mineralocorticoid receptor antagonists);
diuretics (any) |
Matching variables additionally used in the comparison between patients
burdened with psychiatric difficulties that may require
antidepressant/anxyolytic treatment, who were prescribed (Group A) and
not prescribed (Group B) fluvoxamine (Group C by definition is free of
such conditions) |
Matching variables additionally used in the
comparison between patients burdened with psychiatric difficulties that
may require antidepressant/anxyolytic treatment, who were prescribed
(Group A) and not prescribed (Group B) fluvoxamine (Group C by
definition is free of such conditions) |
Matching variables additionally
used in the comparison between patients burdened with psychiatric
difficulties that may require antidepressant/anxyolytic treatment, who
were prescribed (Group A) and not prescribed (Group B) fluvoxamine
(Group C by definition is free of such conditions) |
Dementia |
|
Includes Alzheimer’s dementia (G30, F00), senile
degeneration of the brain (G31.1), vascular dementia, dementia in other
diseases classified elswhere and unspecified dementia (F01-F03),
delirium superimposed on dementia (F05.1) |
Mood disorders |
|
Mood (affective) disorders (F30-F39) |
Nonpsychotic mood disorders |
|
Anxiety, dissiciative, stress-related,
somatoform and other nonpsychotic mood disorders
(F40-F48) |
Substance use |
|
Mental and behavioral disorders due to psychoactive
substance use (F10-F19) |
Non-mood psychotic disorders |
|
Schizophrenia, schizotypal, delusional
and other non-mood psychotic disorders (F20-F29) |
Cumulatively: F50-F59, F60-F69, F70-F79, F80-F89, F90-F98, F04-F09 |
|
Behavioral syndromes associated with physiological disturbances and
physical factors; Disorders of adult personality and behavior;
Intellectual disabilities; Pervasive and specific developmental
disorders; Behavioral and emotional disorders with onset in childhood
and adolescence; mental disorders due to know physiological condition
(F04,05,06, 07, 09). |